Year: 2015
Type: article
Abstract: The commercialisation of scientific research can take place alongside academic discovery and this approach is being supported more widely by universities and funding agencies, where technology transfer arms are now commonplace. A proprietary metabolic labeling assay to measure the production and clearance of biomolecules, developed at the Washington University School of Medicine in Saint Louis, was comercialised with the establishment of C2N Diagnostics. In a University setting, many types of research findings may have potential for commercialization. This is particularly true for academic researchers working on Alzheimer's disease and related disorders. Such findings may be in the area of assay development, diagnostics tests, identification of novel targets, and therapy development. To take full advantage of the potential for development, early disclosure of results to the University office of technology management is critical. Once that has occurred, if commercialization is determined likely worthwhile, there are many potential options including licensing technology to commercial entities to starting new companies. Several successful examples of this will be illustrated in the area of dementia. The licensing of technologies as well as academic spin-out companies, based on robust academic techniques and targets, combined with support from dedicated technology transfer teams, hold great potential for the commercialisation of academic drug discovery.
Source: Alzheimer s & Dementia
Authors: David M. Holtzman, Joel Braunstein
Language: English
Subfield: Information Systems and Management
Field: Decision Sciences
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W2416916888